Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.53 |
| ▸ | GAA | P10253 | 5/20 | 0.53 |
| ▸ | NPC1 | O15118 | 5/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.51 |
| ▸ | MEN1 | O00255 | 4/20 | 0.51 |
| ▸ | RAB9A | P51151 | 4/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | GCGR | P47871 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5364134 | 1.00 | MAPT (0.53) | MAPTGAANPC1KDM4EL3MBTL1 | |
| SCHEMBL5364167 | 0.85 | MAPT (0.71) | MAPTGAANPC1KDM4EL3MBTL1 | |
| SCHEMBL5364159 | 0.85 | MAPT (0.71) | MAPTGAANPC1KDM4EL3MBTL1 | |
| SCHEMBL5364181 | 0.84 | MAPT (0.54) | MAPTGAANPC1KDM4EL3MBTL1 | |
| SCHEMBL5364183 | 0.84 | MAPT (0.54) | MAPTGAANPC1KDM4EL3MBTL1 | |
| SCHEMBL6130278 | 0.83 | HSD17B10 (0.47) | MAPTGAANPC1PTPN1KMT2A | |
| SCHEMBL5369527 | 0.81 | MAPT (0.53) | MAPTGAANPC1KDM4EL3MBTL1 | |
| SCHEMBL5369530 | 0.81 | MAPT (0.53) | MAPTGAANPC1KDM4EL3MBTL1 | |
| SCHEMBL6130299 | 0.81 | MEN1 (0.41) | MAPTGAANPC1KDM4EL3MBTL1 | |
| SCHEMBL5365901 | 0.79 | RAB9A (0.67) | MAPTGAANPC1KDM4EL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7241783-B2 | Thrombopoietin mimetics | SMITHKLINE BEECHAM CORPORATION (US) | 2007-07-10 | — | — | US | claimed |
| EP-1349613-A4 | THROMBOPOIETIN MIMETICS | SMITHKLINE BEECHAM CORP (US) | 2005-09-21 | — | — | EP | claimed |
| US-20040058990-A1 | Thrombopoietin mimetics | SMITHKLINE BEECHAM CORPORATION | 2004-03-25 | — | — | US | claimed |
| EP-1349613-A2 | THROMBOPOIETIN MIMETICS | SmithKline Beecham Corporation (US) | 2003-10-08 | — | — | EP | claimed |
| WO-2002049413-A2 | THROMBOPOIETIN MIMETICS | SMITHKLINE BEECHAM CORPORATION (US) | 2002-06-27 | — | — | WO | claimed |
| US-7241783-B2 | Thrombopoietin mimetics | SMITHKLINE BEECHAM CORPORATION (US) | 2007-07-10 | — | — | US | disclosed |
| EP-1349613-A4 | THROMBOPOIETIN MIMETICS | SMITHKLINE BEECHAM CORP (US) | 2005-09-21 | — | — | EP | disclosed |
| US-20040058990-A1 | Thrombopoietin mimetics | SMITHKLINE BEECHAM CORPORATION | 2004-03-25 | — | — | US | disclosed |
| EP-1349613-A2 | THROMBOPOIETIN MIMETICS | SmithKline Beecham Corporation (US) | 2003-10-08 | — | — | EP | disclosed |
| WO-2002049413-A2 | THROMBOPOIETIN MIMETICS | SMITHKLINE BEECHAM CORPORATION (US) | 2002-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040058990-A1 | Thrombopoietin mimetics | MPL, THPO, TEK | MAPT 4635/4885GAA 3120/4885NPC1 4710/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.